Buy Dulera

Dulera

What is Dulera?

Dulera is a prescription inhaler that combines two active ingredients-mometasone furoate (an inhaled corticosteroid) and formoterol fumarate (a long-acting β₂-agonist). It is supplied as a metered-dose inhaler (MDI) in the fixed-dose strength 6 µg mometasone / 200 µg formoterol per actuation. The product is regulated in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) and is marketed for the maintenance treatment of asthma in patients aged 12 years and older who require additional control beyond an inhaled corticosteroid alone. Dulera is not intended for the relief of acute asthma symptoms.

How Dulera Works in the Body

• Mometasone furoate belongs to the inhaled corticosteroid (ICS) class. After inhalation, it binds to glucocorticoid receptors in airway cells, reducing the production of inflammatory mediators (e.g., cytokines, prostaglandins). This dampens airway inflammation, decreases mucus secretion, and helps prevent airway hyper-responsiveness.
• Formoterol fumarate is a long-acting β₂-agonist (LABA). It stimulates β₂-adrenergic receptors on bronchial smooth muscle, leading to relaxation of the airway and increased airflow. Formoterol has a rapid onset (within minutes) and a prolonged duration of action (≈12 hours), making it suitable for twice-daily dosing.
• The two agents act synergistically: the corticosteroid controls inflammation, while the LABA provides sustained bronchodilation. This combination improves overall asthma control more effectively than either component alone.

Conditions Treated by Dulera

Dulera is authorised by the MHRA for maintenance therapy of asthma in the following patient groups:

• Adults and adolescents (≥ 12 years) whose asthma is not adequately controlled with an inhaled corticosteroid alone.
• Patients who require a single inhaler to deliver both anti-inflammatory and bronchodilator effects.

The inhaler is not approved for:

• Acute relief of bronchospasm (a short-acting β₂-agonist such as salbutamol should be used for rescue).
• Treatment of chronic obstructive pulmonary disease (COPD) or other respiratory conditions unless a clinician specifically decides otherwise.

Patient Suitability and Contraindications

Who Should Use Dulera?

• Individuals aged 12 years and older with a diagnosis of asthma who need regular, twice-daily dosing.
• Patients who can demonstrate correct inhaler technique and are able to follow a prescribed monitoring plan.

Absolute Contraindications

• Known hypersensitivity to mometasone, formoterol, any other component of the inhaler, or to other inhaled corticosteroids or LABAs.
• Episodes of status asthmaticus or uncontrolled severe asthma that require emergency treatment.
• Use of a LABA without an accompanying inhaled corticosteroid (monotherapy with formoterol is prohibited because of an increased risk of asthma-related death).

Relative Contraindications & Precautions

• Pregnancy & lactation: Classified as Pregnancy Category B in the UK. Use only if the potential benefit outweighs potential risks.
• Cardiovascular disease: Caution in patients with severe arrhythmias, coronary artery disease, or hypertension, as LABAs can cause tachycardia or palpitations.
• Thyrotoxicosis or adrenal insufficiency: May exacerbate systemic effects of β₂-agonists or corticosteroids.
• Pediatric patients younger than 12 years: Dulera is not authorised for this age group; alternative paediatric formulations should be considered.
• Severe renal or hepatic impairment: No dose adjustment is formally required, but close monitoring is advised.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Oral thrush (candidiasis) - reported in > 1 % of users; rinse mouth with water after each use.
• Hoarseness or dysphonia - often mitigated by proper inhaler technique and mouth-rinse.
• Headache - mild and transient for many patients.
• Transient tremor - related to the β₂-agonist component; usually resolves without intervention.

Serious Adverse Events

• Paradoxical bronchospasm - sudden worsening of breathing after inhalation; seek emergency care.
• Severe hypersensitivity reactions - rash, angioedema, or anaphylaxis require immediate medical attention.
• Systemic corticosteroid effects (rare at inhaled doses): adrenal suppression, osteoporosis, cataracts, or growth retardation in children.
• Cardiac arrhythmias - especially in patients with pre-existing heart disease or when taken with other sympathomimetics.

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase systemic exposure to mometasone, raising the risk of corticosteroid-related side effects.
• Other β₂-agonists (including short-acting agents) may have additive cardiovascular effects; dose adjustment or monitoring may be needed.
• Diuretics and β-blockers can blunt the bronchodilator response of formoterol.
• Live vaccines - inhaled corticosteroids may modestly suppress immune response; discuss timing with a healthcare professional.

Food and Lifestyle Interactions

• No significant food-drug interactions are known for Dulera.
• Alcohol in moderate amounts does not affect inhaler efficacy, but excessive consumption may worsen asthma control.
• Patients should avoid driving or operating machinery if they experience tremor, palpitations, or dizziness after inhalation.

How to Take Dulera

• Standard dosing: One inhalation (6 µg mometasone + 200 µg formoterol) twice daily, preferably in the morning and in the evening, at least 12 hours apart.
• Inhaler technique:
• Shake the inhaler well before each use.
• Exhale fully, place the mouthpiece between the teeth, close lips around it, and inhale slowly and deeply while pressing the canister once.
• Hold breath for about 10 seconds, then exhale slowly.
• Rinse mouth with water and spit out after each dose; do not swallow.
• Special populations:
• Elderly patients may benefit from a spacer device to ensure optimal drug delivery.
• Patients with severe renal or hepatic impairment should be monitored closely but generally use the same dose.
• Missed dose: If a dose is missed and the interval to the next scheduled dose is > 6 hours, take the missed inhalation as soon as remembered. Do not double the next dose.
• Overdose: Symptoms may include severe tremor, rapid heart rate, palpitations, nausea, or severe cough. Seek emergency medical care; treatment is supportive, and β-blockers may be used under supervision for cardiovascular effects.
• Discontinuation: Abrupt stopping is usually safe, but patients with poorly controlled asthma should discuss a step-down plan with their clinician to avoid loss of control.

Monitoring and Follow-Up

• Lung function tests (spirometry or peak flow) should be performed at baseline and reviewed every 3-6 months, or sooner if symptoms change.
• Symptom diary (daytime and nighttime awakenings, rescue inhaler use) helps assess control.
• Growth monitoring in adolescents is advisable due to the corticosteroid component.
• Ophthalmologic examination is recommended for long-term users (≥ 1 year) to detect cataracts or glaucoma.
• Bone health assessment may be considered for patients on high-dose inhaled steroids for prolonged periods.

Storage and Handling

• Store the inhaler below 30 °C (86 °F), protected from moisture and direct sunlight.
• Keep the canister upright when not in use.
• Do not expose to freezing temperatures.
• Replace the inhaler when the dose counter indicates 0 puffs or if the canister feels unusually heavy.
• Dispose of the empty canister in accordance with local pharmacy-take-back programmes or follow the package instructions for safe disposal.

Medication-Specific Glossary

Inhaled Corticosteroid (ICS)

A medication delivered directly to the lungs to reduce airway inflammation with minimal systemic absorption.

Long-acting β₂-agonist (LABA)

A bronchodilator that relaxes airway smooth muscle for up to 12 hours, used for maintenance therapy rather than immediate symptom relief.

Formoterol

A LABA with a rapid onset of action, allowing it to start working within minutes while providing prolonged bronchodilation.

Mometasone Furoate

A potent glucocorticoid that binds to intracellular receptors to suppress inflammatory gene expression in airway tissues.

Peak Flow

The maximum speed of expiration measured with a peak flow meter; useful for monitoring asthma control at home.

Medical Disclaimer

This article provides educational information about Dulera and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.